Oxitropium

Oxitropium belongs to the Anti-Cholinergics Pharmacological class.

Oxitropium belongs to the pharmacological class of Anticholinergics. Through its action on Muscarinic receptors, Oxitropium appears to inhibit the vagally mediated reflexes by antagonizing the action of acetylcholine which is said to be the transmitter agent released from the vagus nerve.

Metered Dose Inhalation.

1. The cap is removed from the MDI and chamber and Shaken well.
2. The MDI is inserted into the open end of the chamber opposite the mouthpiece.
3. The mouthpiece of the chamber is placed between your teeth and your lips are sealed tightly around it.
4. Now breathe out completely.
5. Then press the canister once.
6. Now breathe in slowly and completely through your mouth. If one hears a "horn-like" sound, then the person is breathing too quickly and needs to slow down.
7. Now hold your breath for 10 seconds and count to 10 slowly to allow the medication to reach the airways of the lung.
8. The above steps are repeated for each puff ordered by medical practitioners and wait about 1 minute in between puffs.
9. Lastly, replace the cap on your MDI when finished.

Oxitropium investigated in the treatment of:

• Pulmonary Disease
• Chronic Obstructive Pulmonary Disease

Oxitropium investigated in the treatment of:

• Pulmonary Disease
• Chronic Obstructive Pulmonary Disease

Metered Dose Inhaler

100ug dose

Metered Dose Inhaler

Maintaining health and smoking cessation is a must.

Caffeine should be avoided or limited to use as it might lead to the risk of nausea, palpitations, nervousness, rapid heartbeat, etc.

Diet containing food with a high glycemic index, saturated and trans fat food, red and processed meat, added sugar, salt, preservatives, refined and high energy-dense foods, low fiber, low antioxidants, and vitamins needs to be restricted.

The dietary restrictions are needed to be individualized as per the patient's requirements.

The adverse effects were noted to be as follows:

• Dry mouth
• Hoarseness
• Bad Taste
• Throat Irritation

• Ruffin RE, FitzgeraldJD, Rebuck AS. A comparison of the bronchodilator activity of Sch 1000 and salbutamol. J Allergy Clin Immunol 1977; 59:136-41 5
• Laitinen LA, Poppius H, Haahtela l: Comparison of ipratropium bromide and salbutamol in a long-term trial in asthmatic and bronchitic patients in a cold climate. Scand J Respir Dis 1979; (suppl 103):163-69 6
• Rebuck AS, Marcus HI. Sch 1000 in psychogenic asthma. Scand J Respir Dis 1979; (suppll03):186-91 7 Alanko K, SahlstrOm K, Harkonen R. Combination of fenoterol and ipratropium bromide in the treatment of bronchial asthma. Eur J Respir Dis 1983; 64(suppll28):546-47 8
• Poppius H, Salorinne Y. Comparative trial ofa new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. Br Med J 1973; 4:134-36 9
• Chan CS, Brown IG, KellyCA, DentAG, Zimmerman p~ Bronchodilator responses to nebulized ipratropium and salbutamol singly and in combination in chronic bronchitis. Br J Clin Pharmacoll984; 17:103-05 10
• Hughes }A, Tobin MJ, Bellamy D, Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982; 37:667-70 11
• Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Eng} J Med 1984; 311: 421-25 12 Nolte D. Double-blind crossover comparison between a P-adrenergic agent and a new anticholinergic agent by metered dose inhaler. Respiration 1978; 36:32-8 13
• Minette A, Marcq M. Oxitropium bromide (Ba 253), an advance in the field of anticholinergic bronchodilator treatments: preliminary results. Rev Inst Hyg Mines 1979; 34:115-23 14
• Flohr E, BischoffKO. Oxitropium bromide, a new anticholinergic drug, in a dose-response and plaCebo comparison in obstructive airway diseases. Respiration 1979; 38:98-104 15
• Beumer HM, Grieben C, Schuijt C, Siebelink J. Oxitropium bromide in bronchial asthma: comparison of metered dose inhaler and powder inhalation of the anticholinergic bronchodilator oxitropium bromide in protection against acetylcholine and histamine provocation. J Clin Pharmacol Ther Toxicoll981; 19:168-70 16
• Sherter CD, Connolly JJ, Schilder D~ The significance of volume-adjusting the maximal mid-expiratory flow in assessing the response to a bronchodilator drug. Chest 1978; 73:568 17
• Schultze-Weminghaus G. Anticholinergic versus p-2-adrenergic therapy in allergic airways obstruction: double-blind trials on bronchodilator effect and anti-allergic protection of oxitropium bromide and fenoterol. Respiration 1981; 41:239-47 18
• Ruffin RE, Newhouse Ml: Ipratropium bromide (Sch 1(00) monohydrate aerosol: bronchodilator effect of three dose levels in asthmatics. Lung 1978; 155:141-46 19
• Hetzel MR, Clark TIH, Houston K. Physiological patterns in early morning asthma. Thorax 1977; 32:418-23 20
• Peel E'I: Anderson G. A dose-response study of oxitropium bromide in chronic bronchitis. Thorax 1984; 39:453-56 21 Peel E'I: Anderson G, Cheong B, Broderick N. A comparison of oxitropium bromide and ipratropium bromide in asthma. Eur J Respir Dis 1984; 65:106-08 22
• Kreubuhler HR, Kyd K, Benoit RC, Scherrer M. The new anticholinergic bronchospasmolytic oxitropium bromide: its long-lasting protective effect through the night. Schweiz Med Wochenschr 1980; 110:812-16 23
• Ponsford JC, Fuller 1M: Saunders KB. A cumulative dose-response study of oxitropium bromide (Ba 253) in asthmatics. Eur J Respir Dis 1983; 64(suppll28):536-39